This study provides valuable outcome information from a real-world cohort of Latin America patients with NSCLC harboring KRAS mutations and emphasizes the prognostic impact of diverse molecular profiles in this genomically-defined subset of lung cancer. The gene discussed is KRAS; the disease is lung carcinoma.